Pre-Close Trading Update

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Pre-Close Trading Update

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces its pre-close trading update ahead of the announcement of its interim results for the six months ended 30 June 2015.

The Group continues to perform well and in line with management's expectations, with sales of approximately £22.8m (H1 2014: £21.4m) in the first half of the year.

Our growth products continue to deliver, with Hydromol™ generating sales of £3.3m in the period, 10% higher than in the same period in the prior year despite the additional PPRS rebate deduction.

MacuShield™, acquired in February this year, is performing in line with expectations and we look forward to the return of ImmuCyst in the second half of the year, although volumes remain uncertain as Sanofi's facility ramps up production.

Alliance continues to explore a number of acquisition opportunities and remains confident of the outlook for the full year.

The Company's interim results for the six months ended 30 June 2015 are scheduled to be released on 9 September 2015.

For further information:

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.